PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.
|Slideshows|October 3, 2017
Case Study: Siblings With Hypotonia in All Limbs
Two young siblings presented to the pediatric department with mental retardation, developmental delay, ataxia, and nystagmus since birth. What's your diagnosis after reviewing the case?
Advertisement
Advertisement
Related to this article
New PREVAIL trial analyses presented at the 2026 AANEM Annual Meeting showed gefurulimab reduced gMG-related hospitalizations and produced durable symptom and quality-of-life gains through one year.
FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.
Here's some of what is coming soon to NeurologyLive® this week.
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is clinical trial results in Alzheimer disease!
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Extends Relutrigine Review, Delays PDUFA to December
3
This Week on NeurologyLive® — September 28, 2026
4
Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis
5